EG BioMed CO., LTD.
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
EG BioMed offers a suite of blood-based cancer detection tests based on cfDNA methylation analysis. By evaluating methylation markers in specific genes associated with cancers — such as breast, colon, and pancreatic cancer — their assays provide early det
Founded Year
2022
Unified Business No.
90190353
Status
Active
Number of Employees
0
Total Paid-in
Capital
230,300,000 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
EG BioMed focuses on leveraging DNA methylation technology to develop non‑invasive blood tests for early cancer detection, prognosis monitoring, and recurrence surveillance. With a precision‑medicine approach, they aim to make cancer screening more accessible and accurate — empowering clinicians with individualized molecular data for better decision‑making.
